|
|
Article: Sirion Building Ophthalmic Pipeline Via Sytera Merger.(Sirion Therapeutics Inc.)
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Continuing its recent flurry of in-licensing activities, ophthalmic drug company Sirion Therapeutics Inc. added a third compound to its clinical pipeline and gained a drug discovery unit through its acquisition of Sytera Inc.
Since it was formed in late December, Sirion's goal has to been to "build a pipeline that's diverse across ophthalmic indications and across different stages of development," said Barry Butler, president and CEO of Tampa, Fla.-based Sirion.
In June, the company licensed its first compound, a topical emulsion product containing the steroid difluprednate for moderate to severe ocular inflammation, from Senju ...